EUVIMEDEUVIMED entdecken
Open Access

GFPT2 drives sunitinib resistance of renal cell carcinoma via enzyme-dependent and -independent manners

Songbo Wang, Jiajun Xing, Xiaoyi Wang, Zengjun Wang, Pengfei Shao, Chenkui Miao

International Journal of Biological Sciences · 2026

DOI: 10.7150/ijbs.118985 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Biological Sciences, 2026. Verfasst von Songbo Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The First Affiliated Hospital of Nanjing Medical University, No. 300 Guangzhou Road, Nanjing, China. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Sunitinib, Drug Resistance, Neoplasm, Kidney Neoplasms. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Intrinsic resistance to sunitinib in advanced renal cell carcinoma (RCC) remains a major barrier to improving patient survival outcomes. However, the molecular mechanisms driving this resistance remain incompletely elucidated. In this study, we first observed elevated glutamine levels in sunitinib-resistant RCC models; notably, glutamine deprivation substantially impaired the growth and proliferation of RCC cells. We further demonstrated that abnormal upregulation of GFPT2-a key enzyme in glutamine metabolism-was associated with reduced sunitinib sensitivity and enhanced drug resistance in RCC. Mechanistically, we uncovered that GFPT2 modulates cellular O-GlcNAcylation levels, which in turn enhances the stability and nuclear translocation of YAP1-ultimately contributing to reduced sunitinib sensitivity. In addition, we also identified an additional non-metabolic role of GFPT2: it directly interacts with the Kelch domain of KEAP1, thereby reducing NRF2 binding to this domain and suppressing NRF2 ubiquitination-dependent degradation. Consequently, this regulatory cascade dysregulates the transcription of downstream antioxidant genes (e.g., HMOX1 and NQO1), ultimately driving NRF2-dependent sunitinib resistance in RCC. Critically, this KEAP1-NRF2 axis-mediated mechanism operates independently of GFPT2's metabolic role in regulating O-GlcNAcylation. Collectively, our findings demonstrate that GFPT2 modulates sunitinib sensitivity and drives drug resistance in RCC via dual mechanisms: a metabolic pathway (O-GlcNAcylation-YAP1) and a non-metabolic pathway (KEAP1-NRF2). Targeting the non-metabolic functions of GFPT2 thus holds promise for enhancing sunitinib sensitivity in RCC while potentially mitigating treatment-related side effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellSunitinibDrug Resistance, NeoplasmKidney NeoplasmsHumansCell Line, TumorAnimalsNF-E2-Related Factor 2Antineoplastic AgentsKelch-Like ECH-Associated Protein 1PyrrolesCell ProliferationTranscription Factors

Stichwörter der Autor:innen

GFPT2O-GlcNAcylationRenal cell carcinomaTKI resistancenon-metabolic function

Substanzen

SunitinibNF-E2-Related Factor 2Antineoplastic AgentsKelch-Like ECH-Associated Protein 1PyrrolesTranscription Factors

Autor:innen und Institutionen

  • Department of Urology, The First Affiliated Hospital of Nanjing Medical University, No. 300 Guangzhou Road, Nanjing, China.
  • Core Facility Center, The First Affiliated Hospital of Nanjing Medical University, No. 300 Guangzhou Road, Nanjing, China.

Zitieren

APA

Wang, S., Xing, J., Wang, X., Wang, Z., Shao, P., & Miao, C. (2026). GFPT2 drives sunitinib resistance of renal cell carcinoma via enzyme-dependent and -independent manners. International Journal of Biological Sciences. https://doi.org/10.7150/ijbs.118985

Vancouver

Wang S, Xing J, Wang X, Wang Z, Shao P, Miao C. GFPT2 drives sunitinib resistance of renal cell carcinoma via enzyme-dependent and -independent manners. International Journal of Biological Sciences. 2026. doi:10.7150/ijbs.118985

BibTeX
@article{Wang2026,
  author = {Wang, Songbo and Xing, Jiajun and Wang, Xiaoyi and Wang, Zengjun and Shao, Pengfei and Miao, Chenkui},
  title = {GFPT2 drives sunitinib resistance of renal cell carcinoma via enzyme-dependent and -independent manners},
  journal = {International Journal of Biological Sciences},
  year = {2026},
  doi = {10.7150/ijbs.118985}
}
Kostenlos starten →